New findings from a recent study investigating the impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the quality of life (QoL) of family members are presented in this touchNEUROLOGY interview by one of the study authors, Dr Nina Muirhead (Doctors with M.E. Director). The results illustrate the significant negative impact on the QoL of partners and other family members, highlighting the difficulties faced by these families and changes that could be made in clinical practice.
- What is known about the impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the quality of life of people with ME/CFS and their family members and what questions remain unanswered? (0.18)
- Could you tell us a little about your recent study and the questionnaires used? (0.56)
- What were the findings in terms of overall health status and FROM-16 score, and what components of these scores had the biggest impact on participants? (1:23)
- What were the strengths and weaknesses of this study? (1:59)
- Following these findings, what changes would you like to see in healthcare systems to acknowledge the impact of ME/CFS? (2:50)
Disclosures: Nina Muirhead in a Director on the advisory board for Doctors with ME
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
A link to the full article can be found here: Impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the quality of life of people with ME/CFS and their partners and family members: an online cross-sectional survey | BMJ Open
Click here for more content from Dr Nina Muirhead
Share this Video
Related Videos In Neuroimmunology
Anthony Béhin, EAN 2023: Safety Profile Overview of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases
Dr Anthony Béhin (University Hospitals Pitié Salpêtrière, Paris, France) discusses his abstract on the safety profile of anti-FcRn drugs, in particular efgartigimod, and anti-complement drugs in the treatment of IgG-mediated autoimmune diseases. The abstract ‘EPR-128 Safety Profile Overview of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases’ was presented at the annual European Academy […]
Highlights from EAN 2023!
Michael Levy: Highlights from the 75th AAN Annual Meeting, 2023
Dr Michael Levy (Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA) provides his highlights from the 75th AAN Annual Meeting, 2023, in particular that this was the first year to have a myelin oligodendrocyte glycoprotein (MOG) antibody disease focus, with posters on two phase 3 trials, which are expected to be presented in 2026. Disclosures: […]